Tempus AI (NASDAQ:TEM) EVP Sells $1,098,762.28 in Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 22,148 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the transaction, the executive vice president owned 146,067 shares in the company, valued at approximately $7,246,383.87. The trade was a 13.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The shares were sold at an average price of $56.00, for a total transaction of $443,912.00.

Tempus AI Stock Up 9.1%

NASDAQ TEM opened at $72.69 on Friday. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The stock has a market cap of $13.12 billion, a PE ratio of -50.48 and a beta of 3.58. The firm has a 50-day simple moving average of $52.93 and a 200 day simple moving average of $51.36. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.22) earnings per share. On average, research analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently added to or reduced their stakes in the stock. GC Wealth Management RIA LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $399,267,000. Voloridge Investment Management LLC lifted its holdings in shares of Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at $54,020,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TEM has been the topic of a number of research reports. Lake Street Capital cut Tempus AI to a “hold” rating in a research report on Monday, July 20th. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Piper Sandler decreased their price target on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 4th. HC Wainwright lowered their price target on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $65.69.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.